pharma · Non Small Cell Lung Cancer · Locally Advanced Solid Tumor · TNGX
Tango Therapeutics
Tango Therapeutics patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2017
- Employees
- 154
- Programs
- 7
- Drugs
- 2
- Patents
- 9
Tango Therapeutics patents
9 pharmaceutical patents indexed for Tango Therapeutics. 0 expire within 24 months.
Tango Therapeutics has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12403137
Compounds and methods of use
granted -
US 12304907
Compounds and methods of use
granted -
US 12264154
Compounds and methods of use
granted -
US 12043607
HDAC inhibitors and therapeutic use thereof
granted -
US 11999727
Compounds and methods of use
granted -
US 11986471
Compounds and methods of use
granted -
US 11492350
Compounds and methods of use
granted -
US 11077101
Compounds and methods of use
granted -
US 9095624
Modular transport platform for targeted delivery of therapeutic agents
granted
Frequently asked questions
How many patents does Tango Therapeutics have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Tango Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.